硫辛酸联合吡格列酮治疗早期糖尿病肾病临床研究被引量：1

下载PDF

导出

摘要目的:观察硫辛酸联合吡格列酮治疗早期糖尿病肾病的临床疗效。方法:将早期糖尿病肾病120例随机分为对照组、硫辛酸组、吡格列酮组及联用组各30例,均给予正规胰岛素或降糖药降糖、ARB降压;三个用药组分别应用硫辛酸(600mg/d)、吡格列酮(30mg/d)及两药联用2周后,观察四组患者24小时尿蛋白(Up)、尿微量白蛋白(24h MALB)及C反应蛋白(CRP)水平的变化。结果:三个用药组Up、24h MALB及CRP水平均较治疗前明显下降(P<0.05),联合用药组低于对照组、硫辛酸组和吡格列酮组(P<0.05)。结论:硫辛酸和吡格列酮联合应用是治疗早期糖尿病肾病的有效方法。

作者牛永菡陈桂芝邓延华

机构地区山东省青岛市胶州中心医院

出处《中国民康医学》 2013年第22期50-50,109,共2页 Medical Journal of Chinese People’s Health

关键词早期糖尿病肾病硫辛酸吡格列酮

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1Vasavada N, Agarwal R. Role of oxidative stress in diabetic ne- phropathy [ J ]. Adv Chronic Kidney Dis, 2005,12 ( 2 ) : 146 - 154. 被引量：1
2林善锬.糖尿病肾病[J].中华内科杂志,2005,44(3):229-231. 被引量：117
3方岐莹,邵凤民.糖尿病肾病的发病机制及治疗新进展[J].实用诊断与治疗杂志,2008,22(3):201-203. 被引量：29
4Jeong KH, Lee TW, Ihm CG, et al. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin - induced diabetic rats [ J]. Am J Nephro1,2009,29 ( 3 ) :274 - 282. 被引量：1
5Da Ros R, Assaloni R, Ceriello A. Molecular targets of diabetic vas- cular complications and potential new drugs [ J ]. Curr Drug Tar- gets ,2005,6 : 503 - 509. 被引量：1
6Tailleux L, Schwartz O, Herrmann JL et al. DC - SIGN is the major Mycobact erium tuberculosis receptor on human dendritic cells [J].JExpMed,2003;197(1) : 121 -127. 被引量：1
7Evans JL, Goldfine ID, Maddux BA,et al. Arc oxidative stress acti- vated signaling pathways mediators of insulin resistanec and beta- cell dysfunction [ J ]. Diabetes,2003,52 ( 1 ) : 1 - 8. 被引量：1

二级参考文献34

1Adler SG, Pahl M, Seldin MF.Deciphering diabetic nephropathy: progress using genetic strategies.Curr Opin Nephrol Hypertens,2000,9:99-106. 被引量：1
2Lansang MC, Hollenberg NK.Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked?Diabetes,2002,51:2025-2028. 被引量：1
3Volker V, Roland CB, Scott T, et al. Glomerular hyperfiltration and the salt paradox in rarly type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol, 2003,14:530-537. 被引量：1
4Sheetz MJ, King GL.Molecular understanding of hyperglycemia's adverse effects for diabetic complications.JAMA,2002,288:2579-2588. 被引量：1
5Brownlee M. Biochemistry and molecular cell biology of diabetic complications.Nature,2001,414:813-820. 被引量：1
6Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.Diabetes,2002,51:3274-3282. 被引量：1
7Evans JL, Goldfine ID, Maddux BA,et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev, 2002,23:599-622. 被引量：1
8White KE, Bilous RW, Marshall SM, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria.Diabetes,2002,51:3083-3089. 被引量：1
9Batlle D. Clinical and cellular markers of diabetic nephropathy.Kidney Int,2003,63:2319-2330. 被引量：1
10Kveder R, Kajtna-Koselj M, Rott T, et al. Nephrotic syndrome in patients with diabetes mellitus is not always associated with diabetic nephropathy.Nephrol Dial Transplant,2001,16 Suppl 6:86-87. 被引量：1